Delving into the Latest Updates on Shanghai Xintan Venture Capital Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

κ opioid receptor x μ opioid receptor	1

To compare the total amount of morphine used within 48 hours after surgery between the senabuphine long-acting injection group and the placebo group to evaluate the effectiveness of senabuphine long-acting injection in relieving postoperative pain. To evaluate the safety of senabuphine long-acting injection in relieving postoperative pain.

Start Date04 Jun 2021

Sponsor / Collaborator

Lumosa Therapeutics Co., Ltd.

[+2]

100 Clinical Results associated with Shanghai Xintan Venture Capital Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Xintan Venture Capital Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Xintan Venture Capital Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Xintan Venture Capital Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data